# A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

> **NCT02141295** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 197 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** 5-FU
- **DRUG:** Bevacizumab
- **DRUG:** Folinic acid
- **DRUG:** Oxaliplatin
- **DRUG:** Vanucizumab

## Key facts

- **NCT ID:** NCT02141295
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-30
- **Primary completion:** 2016-07-29
- **Final completion:** 2017-02-01
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2020-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141295, "A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02141295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*